Elcin-Guinot S, Lagies S, Avi-Guy Y, Neugebauer D, Huber T, Schell C
Int J Mol Sci. 2025; 26(5).
PMID: 40076891
PMC: 11900420.
DOI: 10.3390/ijms26052272.
Levstek T, Bahcic E, Vujkovac B, Cokan Vujkovac A, Tesovnik T, Remec Z
Cells. 2025; 14(3).
PMID: 39937009
PMC: 11817696.
DOI: 10.3390/cells14030218.
Monte Neto J, Mastroianni Kirsztajn G
J Bras Nefrol. 2024; 46(3):e20240035.
PMID: 39058283
PMC: 11287863.
DOI: 10.1590/2175-8239-JBN-2024-0035en.
Tolerico M, Merscher S, Fornoni A
Cells. 2024; 13(11).
PMID: 38891023
PMC: 11171506.
DOI: 10.3390/cells13110890.
Rozenfeld P, Feriozzi S, Braun F
Front Cardiovasc Med. 2024; 11:1386042.
PMID: 38646152
PMC: 11027898.
DOI: 10.3389/fcvm.2024.1386042.
Case report: mutation of a-galactosidase A in a female patient with end-stage renal disease: report of a case of late diagnosis of Anderson-Fabry disease.
Simonetta I, Riolo R, Todaro F, Donadio V, Incensi A, Miceli S
Front Genet. 2023; 14:1122893.
PMID: 37779915
PMC: 10537954.
DOI: 10.3389/fgene.2023.1122893.
TFEB-mediated lysosomal exocytosis alleviates high-fat diet-induced lipotoxicity in the kidney.
Nakamura J, Yamamoto T, Takabatake Y, Namba-Hamano T, Minami S, Takahashi A
JCI Insight. 2023; 8(4).
PMID: 36649084
PMC: 9977505.
DOI: 10.1172/jci.insight.162498.
Genetic Susceptibility to Chronic Kidney Disease: Links, Risks and Management.
Sawaf H, Gudura T, Dorobisz S, Sandy D, Wang X, Bobart S
Int J Nephrol Renovasc Dis. 2023; 16:1-15.
PMID: 36636322
PMC: 9831004.
DOI: 10.2147/IJNRD.S363041.
Kidney Podocyte Zebra Bodies after Lung Transplantation for Lymphangioleiomyomatosis.
Ishide T, Nishi H, Miyano S, Hirakawa Y, Honda K, Abe H
Intern Med. 2022; 62(13):1965-1970.
PMID: 36351586
PMC: 10372279.
DOI: 10.2169/internalmedicine.0882-22.
Biomarkers for Monitoring Renal Damage Due to Fabry Disease in Patients Treated with Migalastat: A Review for Nephrologists.
Jaurretche S, Conde H, Gonzalez Schain A, Ruiz F, Sgro M, Venera G
Genes (Basel). 2022; 13(10).
PMID: 36292636
PMC: 9601519.
DOI: 10.3390/genes13101751.
Galactomannan-Decorated Lipidic Nanocarrier for Gene Supplementation Therapy in Fabry Disease.
Rodriguez-Castejon J, Gomez-Aguado I, Beraza-Millor M, Solinis M, Del Pozo-Rodriguez A, Rodriguez-Gascon A
Nanomaterials (Basel). 2022; 12(14).
PMID: 35889565
PMC: 9324688.
DOI: 10.3390/nano12142339.
The Impact of Kidney Biopsy for Fabry Nephropathy Evaluation on Patients' Management and Long-Term Outcomes: Experience of a Single Center.
Rusu E, Zilisteanu D, Ciobotaru L, Gherghiceanu M, Procop A, Jurcut R
Biomedicines. 2022; 10(7).
PMID: 35884826
PMC: 9313342.
DOI: 10.3390/biomedicines10071520.
Hydroxychloroquine and Fabry Disease: Three Case Reports Examining an Unexpected Pathologic Link and a Review of the Literature.
Sen R, Borghoff K, Foster K, Radio S, Erickson A, Hearth-Holmes M
Case Rep Rheumatol. 2022; 2022:2930103.
PMID: 35860433
PMC: 9293550.
DOI: 10.1155/2022/2930103.
Hematopoietic Disorders, Renal Impairment and Growth in Mucopolysaccharidosis-Plus Syndrome.
Sofronova V, Iwata R, Moriya T, Loskutova K, Gurinova E, Chernova M
Int J Mol Sci. 2022; 23(10).
PMID: 35628659
PMC: 9145135.
DOI: 10.3390/ijms23105851.
Implications of Sphingolipid Metabolites in Kidney Diseases.
Mallela S, Merscher S, Fornoni A
Int J Mol Sci. 2022; 23(8).
PMID: 35457062
PMC: 9025012.
DOI: 10.3390/ijms23084244.
Arrhythmias in Chronic Kidney Disease.
Akhtar Z, Leung L, Kontogiannis C, Chung I, Bin Waleed K, Gallagher M
Eur Cardiol. 2022; 17:e05.
PMID: 35321526
PMC: 8924956.
DOI: 10.15420/ecr.2021.52.
Improvement in Decline Rate of Estimated Glomerular Filtration Rate after Febuxostat Treatment in a Fabry Disease Patient with Enzyme Replacement Therapy-resistant Proteinuria.
Kume S, Yasuda-Yamahara M, Imamura-Uehara Y, Kuwagata S, Yamahara K, Takeda N
Intern Med. 2022; 61(20):3077-3081.
PMID: 35283375
PMC: 9646352.
DOI: 10.2169/internalmedicine.8993-21.
Reduced α-galactosidase A activity in zebrafish ( mirrors distinct features of Fabry nephropathy phenotype.
Elsaid H, Furriol J, Blomqvist M, Diswall M, Leh S, Gharbi N
Mol Genet Metab Rep. 2022; 31:100851.
PMID: 35242583
PMC: 8857658.
DOI: 10.1016/j.ymgmr.2022.100851.
Podocyturia in Fabry disease: a 10-year follow-up.
Vujkovac B, Kirbis I, Keber T, Cokan Vujkovac A, Tretjak M, Rados Krnel S
Clin Kidney J. 2022; 15(2):269-277.
PMID: 35145641
PMC: 8824799.
DOI: 10.1093/ckj/sfab172.
Fabry nephropathy before and after enzyme replacement therapy: important role of renal biopsy in patients with Fabry disease.
Kim I, Lee H, Cheon C
Kidney Res Clin Pract. 2021; 40(4):611-619.
PMID: 34922431
PMC: 8685354.
DOI: 10.23876/j.krcp.21.056.
